• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , April 18

SHANTHA Biotechnics has launched Jencevac, a vaccine for combating Japanese Encephalitis (JE), commonly known as brain fever, in the domestic market.

The product would be available as 5 ml multi-dose injection for easy vaccination.

In a release here on Monday, Shantha Biotech said it has formed a partnership with Korea-based Green Cross Vaccine Corporation for distribution and marketing of Jencevac in India.

Commenting on the launch, the Shantha Biotech Managing Director, Mr K. I. Varaprasada Reddy, said, "Jencevac is produced using the inactivated Nakayama strain known for its good propagation characteristics and its strength to provide cross-protection against other JE viral strains."

JE outbreaks have also occurred in 25 States and Union Territories of India. The period of transmission starts in April or May, and lasts until December in India.

Till date, there is no treatment for JE, except for providing symptomatic relief to infected persons. However, JE vaccination is the single most important control measure, the release said.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Parry's plans to brand non-refined sugar

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line